COPENHAGEN, Denmark, July 30, 2015 (GLOBE NEWSWIRE) -- Zealand informs that the company has received a major shareholder announcement from Bpi Groupe, 27-31 AV du General Leclerc, 94700 Maisons-Alfort, France (French registration no. 507 523 678 R.C.S. Creteil).
As stated in Company Announcement no. 6/2015 of 18 March 2015, Innovation Capital no longer manages nor controls the voting rights of CDC Entreprises Capital Investissement ("CDC ECI").
CDC ECI is controlled by Bpi France Participation which is controlled by Bpi Groupe.
Pursuant to Section 29 of the Danish Securities Act, cf. Executive order no. 668 of 25 June 2012 on major shareholders and the Danish Companies Act section 55, cf. section 56, it has been announced to Zealand that Bpi Groupe (via its subsidiary CDC ECI) indirectly holds nominally DKK 1,190,215 shares in Zealand Pharma A/S, corresponding to 5.06 % of the company's share capital and voting rights.
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: email@example.com
About Zealand Pharma
Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) is a biotechnology company with world leading expertise in the identification, design and development of novel peptide-based medicines, with competences spanning also in-house clinical trial design and management. The company is advancing a proprietary pipeline of novel medicines alongside a portfolio of products and development projects under license collaborations - and with a therapeutic focus in the fields of metabolic diseases and acute care indications.
Zealand's first invented medicine, lixisenatide, is a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, which is marketed globally (ex-US) as Lyxumia(r) under a license agreement with Sanofi, covering also LixiLan, a new fixed-ratio combination of lixisenatide and insulin glargine (Lantus(r)) in Phase III development. Lixisenatide was submitted for regulatory approval in the US in late July 2015, and filings for LixiLan are planned for Q4 2015 in the US and Q1 2016 in the EU.
The proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two clinical programs; a single-use rescue pen (severe hypoglycemia) in preparation for Phase II and a multiple-dose version (mild to moderate hypoglycemia) in Phase I, as well as several preclinical peptide therapeutics.
Zealand currently has global license agreements and collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand is based in Copenhagen, Denmark. For further information: www.zealandpharma.com and follow us on Twitter @ZealandPharma.
Source: Zealand Pharma A/S